


HYDROXYZINE HYDROCHLORIDE - hydroxyzine hydrochloride tablet, film coated
H.J. Harkins Company, Inc.

HYDROXYZINE HYDROCHLORIDE
TABLETS, USP
Rx only

DESCRIPTION

HydrOXYzine hydrochloride has the chemical name of 2-[2-[4-(p-Chloro- α -phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride.



HydrOXYzine hydrochloride occurs as a white, odorless powder which is very soluble in water.

Each tablet for oral administration contains 10 mg, 25 mg or 50 mg hydrOXYzine HCl. Inactive ingredients include: lactose monohydrate, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, stearic acid, polyethylene glycol, polysorbate 80, and titanium dioxide.

CLINICAL PHARMACOLOGY

HydrOXYzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. HydrOXYzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system.

Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated.

Pharmacological and clinical studies indicate that hydrOXYzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

HydrOXYzine is rapidly absorbed from the gastrointestinal tract and hydrOXYzine's clinical effects are usually noted within 15 to 30 minutes after oral administration.

INDICATIONS AND USAGE

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and

contact dermatoses, and in histamine-mediated pruritus.

As a sedative when used as a premedication and following general anesthesia, **hydrOXYzine may potentiate meperidine and barbiturates**, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. HydrOXYzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.

The effectiveness of hydrOXYzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

CONTRAINDICATIONS

HydrOXYzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydrOXYzine is contraindicated in early pregnancy.

HydrOXYzine is contraindicated for patients who have shown a previous hypersensitivity to it.

WARNINGS

Nursing Mothers

It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydrOXYzine should not be given to nursing mothers.

PRECAUTIONS

THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydrOXYzine their dosage should be reduced.

Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydrOXYzine. Patients should also be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.

Geriatric Use

A determination has not been made whether controlled clinical studies of hydrOXYzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

The extent of renal excretion of hydrOXYzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydrOXYzine and observed closely.

ADVERSE REACTIONS

Side effects reported with the administration of hydrOXYzine hydrochloride are usually mild and transitory in nature.

Anticholinergic: Dry mouth.

Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

OVERDOSAGE

The most common manifestation of hydrOXYzine overdosage is hypersedation. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydrOXYzine counteracts its pressor action.

There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydrOXYzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydrOXYzine in body fluids or tissue after its ingestion or administration.

DOSAGE AND ADMINISTRATION

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: Adults, 50-100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50-100 mg daily in divided doses.

For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50-100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50-100 mg for adults and 0.6 mg/kg of body weight in children.

When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.

As with all potent medication, the dosage should be adjusted according to the patient's response to therapy.

HOW SUPPLIED

HydrOXYzine Hydrochloride Tablets, USP,

10 mg - Round, white, film-coated tablet, debossed "H/105", supplied in bottles of 100, 500, and 1000.

Bottles of 100 **NDC 23155-105-01**

Bottles of 500 **NDC 23155-105-05**

Bottles of 1000 **NDC 23155-105-10**

25 mg - Round, white, film-coated tablet, debossed "H/106", supplied in bottles of 100, 500, and 1000.

Bottles of 100 **NDC 23155-106-01**

Bottles of 500 NDC 23155-106-05
Bottles of 1000 NDC 23155-106-10

50 mg - Round, white, film-coated tablet, debossed "H/107", supplied in bottles of 100, 500, and 1000.

Bottles of 100 NDC 23155-107-01
Bottles of 500 NDC 23155-107-05
Bottles of 1000 NDC 23155-107-10

Dispense in a tight container as defined in the USP.

Store at controlled room temperature 20°-25°C (68°-77°F); [see USP Controlled Room Temperature].

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Manufactured for:
Heritage Pharmaceuticals Inc.
Edison, NJ 08837
1.866.901.DRUG (3784)

Manufactured by:
ANDAPharm,LLC
Ft. Lauderdale, FL 33309

Repacked by:
H.J. Harkins Company, Inc.
Nipomo, CA 93444

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

52959-074-90 RX Only: #XXXXXXXXX #XXX

HYDROXYZINE HCL. 25mg TABLET

Lot #: HOY200ZQ
Mfg: HERITAGE
Exp: 01/13 Compare to: Atarax
Mfg Ft. Mfg. NDC: 23155-106-01
Loc.: Lauderdale, FL Pill ID: White round film-coated tablet

CAUTION: Federal law PROHIBITS the transfer of this drug to anyone other than the person to whom prescribed and prohibits dispensing without a prescription unless OTC. See outsert for add'l RX info KEEP OUT OF REACH OF CHILDREN. Store in a cool dry place 68 to 77 degrees F.

HYDROXYZINE HCL. 25mg TABLET			
52959-074-90	Qty	#90	
01/13	Lot	HOY200ZQ	
Atarax		23155-106-01	

HYDROXYZINE HCL. 25mg TABLET			
52959-074-90	Qty	#90	
01/13	Lot	HOY200ZQ	
Atarax		23155-106-01	

HYDROXYZINE HCL. 25mg TABLET			
52959-074-90	Qty	#90	
01/13	Lot	HOY200ZQ	
Atarax		23155-106-01	

HYDROXYZINE HCL. 25mg TABLET			
52959-074-90	Qty	#90	
01/13	Lot	HOY200ZQ	
Atarax		23155-106-01	

Take as directed by your Doctor or
See outsert for usual dosage information

Repack: HJ Harkins Co., Inc. Nipomo, CA 93444
Dispense in tight, child & light-resistant container per USP

HYDROXYZINE HYDROCHLORIDE

hydroxyzine hydrochloride tablet, film coated

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:52959-074(NDC:23155-106)
---------------------	-------------------------	---------------------------	------------------------------

Route of Administration	ORAL
--------------------------------	------

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
HYDRO XYZINE HYDRO CHLORIDE (UNII: 76755771U3) (HYDRO XYZINE - UNII:30S50YM8OG)	HYDRO XYZINE HYDROCHLORIDE	25 mg

Inactive Ingredients	
Ingredient Name	Strength
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
SILICON DIO XIDE (UNII: ETJ7Z6XBU4)	
HYPROMELLOSES (UNII: 3NXW29V3WO)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	
STEARIC ACID (UNII: 4ELV7Z65AP)	
POLYETHYLENE GLYCOL (UNII: 3WJQ0SDW1A)	
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	
TITANIUM DIO XIDE (UNII: 15FIX9V2JP)	

Product Characteristics			
Color	WHITE	Score	no score
Shape	ROUND	Size	8mm
Flavor		Imprint Code	H;106
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:52959-074-12	12 in 1 BOTTLE		
2	NDC:52959-074-13	13 in 1 BOTTLE		
3	NDC:52959-074-15	15 in 1 BOTTLE		
4	NDC:52959-074-16	16 in 1 BOTTLE		
5	NDC:52959-074-20	20 in 1 BOTTLE		
6	NDC:52959-074-21	21 in 1 BOTTLE		
7	NDC:52959-074-24	24 in 1 BOTTLE		
8	NDC:52959-074-30	30 in 1 BOTTLE		
9	NDC:52959-074-40	40 in 1 BOTTLE		
10	NDC:52959-074-50	50 in 1 BOTTLE		
11	NDC:52959-074-60	60 in 1 BOTTLE		
12	NDC:52959-074-90	90 in 1 BOTTLE		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

ANDA	ANDA040804	06/30/2008	
------	------------	------------	--

Labeler - H.J. Harkins Company, Inc. (147681894)

Registrant - H.J. Harkins Company, Inc. (147681894)

Establishment			
Name	Address	ID/FEI	Business Operations
H.J. Harkins Company, Inc.		147681894	repack, relabel

Revised: 1/2012

H.J. Harkins Company, Inc.